However, we observed that activated AKT level underwent a decrease followed by a rebound in BRAF-mutant CRC cell RKO and gradually increased in wild-type CRC cell Caco2, which might impair the anti-tumor effect of SHP2 inhibitor. This evidence concerns the gene PTPN11 and colorectal carcinoma.